David M Rayner 26th Lorne Cancer Conference 2014

Abstracts this author is presenting:

• Shifting doxorubicin activity from topoisomerase-2 poison to adduct formation reduces cardiotoxicity while maintaining anticancer efficacy — Poster Session 2